News

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance


 

Objectives: This randomized phase III trial asks whether a "MEAL program intervention," including dietary education and telephone counseling sessions over 24 months, can alter disease progression when compared with information on standard U.S. Dietary Guidelines.

Key entry or exclusion criteria: Patients should be 50-80 years of age with biopsy-proven disease up to clinical stage T2a and no distant metastases.

Locations: 120 sites.

Goal: 464 patients.

Study sponsor: Cancer and Leukemia Group B in collaboration with the National Cancer Institute.

Link for more information: clinicaltrials.gov/ct2/show/NCT01238172

NIH clinical trials identifier: NCT01238172

Recommended Reading

Pazopanib Edges Sunitinib as First-Line Kidney Cancer Therapy
MDedge Hematology and Oncology
Abiraterone and Enzalutamide Thwart Prostate Cancer Pain
MDedge Hematology and Oncology
Lenalidomide Worsens Survival in Advanced Prostate Cancer
MDedge Hematology and Oncology
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Patients with Advanced Urinary Tract Cancer
MDedge Hematology and Oncology
Safety and Efficacy Study of Enzalutamide versus Bicalutamide in Men With Prostate Cancer (STRIVE)
MDedge Hematology and Oncology
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Patients With High-Risk Localized Prostate Cancer
MDedge Hematology and Oncology
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Patients with High-Risk Prostate Cancer
MDedge Hematology and Oncology
Radiation Therapy With or Without Androgen-Deprivation Therapy in Patients with Prostate Cancer
MDedge Hematology and Oncology
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
MDedge Hematology and Oncology
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Patients with a Rising PSA after Surgery for Prostate Cancer
MDedge Hematology and Oncology